We report on the successful use of oral ciprofloxacin and doxycycline in the treatment of multiple subcutaneous nocardial abscesses in an immunocompromised patient with active non-Hodgkin's lymphoma. This relatively inexpensive regimen allowed the patient to return home and was not associated with any significant side effects. The patient has shown no sign ofrelapse ofher nocardial infection over an 8-month period on the above regimen.
The remaining abscesses were surgically drained. Ten days later culture of the pus yielded Nocardia asteroides and benzylpenicillin was stopped. The patient was otherwise well and had no symptoms or signs of pulmonary or central nervous system disease. The chest X-ray was normal. The patient became pancytopenic and although chlorambucil-induced marrow suppression was suspected the co-trimoxazole was stopped after 7 days of treatment and substituted with intravenous cefuroxime and amikacin. After 7 days of this regimen the in vitro sensitivities of the organism were available and were as follows: sensitive to ciprofloxacin (minimum inhibitory concentration -MIC 1 mg/l), doxycycline, amoxycillin-clavulanic acid, amikacin (MIC 2 mg/l) and cefuroxime (MIC 1 mg/l); resistant to sulphamethoxazole, trimethoprim, co-trimoxazole and amoxycillin.
Her parenteral antibiotics were then changed to oral therapy with ciprofloxacin (500 mg twice daily) and doxycycline (200 mg then 100 mg once daily). She became pain free and two of the three abscesses ceased draining after 10 weeks. Pus from the third and largest abscess remained sterile and it healed after 4 months of therapy. Apart from intermittent diarrhoea (Clostridium difficile toxin negative) which required codeine phosphate there were no side effects. It is planned to continue treatment for a total period of 9 months.
Discussion
Although Nocardia asteroides usually causes infection in immunocompromised patients, especially those with lymphoma, it may also infect the immunocompetent. 2 Local infection may become disseminated to the lungs, central nervous system or skin when the prognosis becomes poor. Other poor prognosticators include immunosuppression from drugs or disease.3
The organism is usually sensitive to co-trimoxazole which is considered to be the drug of choice.' Therapy with two agents, as in co-trimoxazole, may offer advantages and treatment is recommended for up to a year. 4 Ciprofloxacin is a new 4-quinolone antibacterial agent with excellent tissue penetration and a high volume of distribution reflecting good diffusion into the extravascular space.' It has been used successfully for the treatment of severe infections in immunocompromised patients.6 An oral preparation is available for twice daily administration and adverse effects are uncommon. In vitro studies suggest that ciprofloxacin should be effective in the treatment of nocardial infections.79 One case report describes the use of ciprofloxacin in the treatment of acquired immunodeficiency syndrome-related nocardial pneumonia;'0 there was no improvement and therapy was changed to imipenem. Tetracycline derivatives have been used with success in the treatment of nocardia infections. The pharmacokinetics of doxycycline in particular suggest that it would be an effective agent for the treatment of soft tissue nocardia infections."
We believe that healing of the subcutaneous abscesses and prevention of further dissemination of the organism in our patient indicate that the combination of ciprofloxacin and doxycycline may be considered for the treatment of infections due to Nocardia asteroides when co-trimoxazole cannot be used (because of resistance on the part of the organism, allergy or concern about marrow suppression). This combination constitutes a simple, oral and moderately priced regimen allowing patients to be discharged home after initial parenteral therapy has ceased. 
